Drug intelligence / Profile preview

Ba-ISTAb

Development stage: Preclinical
Lead developer: Integrated BioTherapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

Ba-ISTAb is an engineered monoclonal antibody developed by Integrated BioTherapeutics for the treatment of anthrax caused by Bacillus anthracis. It is designed as an anti-protective antigen (anti-PA) neutralizing antibody that targets the surface of B. anthracis, aiming to achieve both toxin neutralization and bacterial clearance. The drug acts as a cell wall inhibitor and is intended for use in inhalation anthrax, with preclinical development ongoing in the United States[1][3][5].

Other names: ISTAb against Bacillus anthracisanti-PA neutralizing antibody targeted to B. anthracis

Targets

PA (Influenza polymerase acidic protein)

Beyond the preview

Go deeper on Ba-ISTAb.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ba-ISTAb.

Explore the full profile